Boston: Hologic, Inc. (Nasdaq: HOLX) has announced a definitive agreement to be acquired by funds managed by Blackstone and TPG. The transaction is valued at up to $79 per share, translating to an enterprise value of up to $18.3 billion.

According to BERNAMA News Agency, the terms of the agreement stipulate that Blackstone and TPG will purchase all outstanding Hologic shares for $76 per share in cash. In addition, a non-tradable contingent value right (CVR) will be offered, allowing shareholders to receive up to $3 per share in two separate payments of up to $1.50 each. This brings the total potential consideration to $79 per share in cash. The CVR will be issued to Hologic stockholders at the closing of the deal and will be paid, either in full or partially, contingent upon meeting specific global revenue targets for Hologic's Breast Health business in fiscal years 2026 and 2027.